Details der Publikation - A vaccine and a device used together to treat women with precancerous cells on the cervix caused by human papillomavirus (HPV).

A vaccine and a device used together to treat women with precancerous cells on the cervix caused by human papillomavirus (HPV). : A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) OF THE CERVIX - Randomized Evaluation of VGX-3100 and Electroporation for the treatment of Cervical dysplasia REVEAL

Medienart:	Klinische Studie

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	WHO International Clinical Trials Registry Platform - (2023) vom: 21. Juni Zur Gesamtaufnahme - year:2023

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) OF THE CERVIX MedDRA version: 21.1Level: PTClassification code 10064328Term: Human papilloma virus test positiveSystem Organ Class: 10022891 - Investigations MedDRA version: 21.1Level: LLTClassification code 10066237Term: Cervical high grade squamous intraepithelial lesionSystem Organ Class: 100000004872;Therapeutic area: Diseases [C] - Virus Diseases [C02] Phase: Phase 3 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 24-07-2017, Last updated: 2023-06-29

ICTRP ID:	EUCTR2016-002761-63-GB HPV-301 NCT03185013

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG004707907

Internformat


LEADER	01000caa a22002652 4500
001	CTG004707907
003	DE-627
005	20230629100628.0
007	cr uuu---uuuuu
008	210507s2023 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)CTG004707907
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2016-002761-63-GB
035			\|a (UBBS_Klinische_Studien_WHO)HPV-301
035			\|a (UBBS_Klinische_Studien_WHO)NCT03185013
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a A vaccine and a device used together to treat women with precancerous cells on the cervix caused by human papillomavirus (HPV). \|b A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) OF THE CERVIX - Randomized Evaluation of VGX-3100 and Electroporation for the treatment of Cervical dysplasia REVEAL
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 24-07-2017, Last updated: 2023-06-29
650		4	\|a Medical Condition: HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) OF THE CERVIX MedDRA version: 21.1Level: PTClassification code 10064328Term: Human papilloma virus test positiveSystem Organ Class: 10022891 - Investigations MedDRA version: 21.1Level: LLTClassification code 10066237Term: Cervical high grade squamous intraepithelial lesionSystem Organ Class: 100000004872;Therapeutic area: Diseases [C] - Virus Diseases [C02]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 3
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2023) vom: 21. Juni
773	1	8	\|g year:2023 \|g day:21 \|g month:06
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002761-63 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
951			\|a AR
952			\|j 2023 \|b 21 \|c 06

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände